Abstract
Introduction The extent to which genetic variation at the APOE locus explains the burden of late-onset Alzheimer’s disease (AD) is poorly understood. We aimed to provide new estimates of the proportions of AD and all-cause dementia attributable to combined carriage of ε3 and/or ε4 alleles of APOE.
Methods We conducted a nested case-control study using data from 171,133 participants of the UK Biobank cohort study, aged ≥60 years at baseline assessments in 2006-2010. Carriage of ε2/ε3/ε4 alleles of APOE were coded from genotyped or imputed microarray data for single nucleotide polymorphisms rs7412 and rs429358. AD and all-cause dementia were ascertained from baseline self-report and follow-up via linked electronic health and death records up to December 2022 (minimum/maximum follow-up: 12.2 / 16.8 years). Risks of these outcomes due to ε3 and/or ε4 carriage were modelled with multivariable logistic regression, adjusting for age at baseline, self-reported sex and ethnicity, 10 genetic principal components and genotyping array. Odds ratios and prevalence of ε3 and ε4 carriage were used to calculate population attributable fractions (PAFs) of the outcomes due to these genotypes.
Results 99.4% of the sample had either ε3 and/or ε4 carriage. By the end of follow-up, 3026 (1.8%) and 6634 (3.9%) of the sample had AD and all-cause dementia, respectively. The odds ratio for AD risk due to ε3 and ε4 carriage with reference to ε2 homozygotes was 3.80 (95% CI:1.58, 9.17). The equivalent risk for all-cause dementia was 1.74 (95% CI: 1.16, 2.61). PAFs for AD and all-cause dementia burden due to ε3 and ε4 exposure were 73.6% (95% CI: 36.6, 89.0) and 42.4% (95% CI: 13.6, 61.6%), respectively.
Conclusions Differences in the molecular physiology of Apolipoprotein E cause most AD and a large fraction of dementia cases. Research into this pathway should be prioritised to facilitate dementia prevention.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The MRC Unit for Lifelong Health and Ageing at UCL is funded by the Medical Research Council (MC_UU_00019/3). NMD is supported via a Norwegian Research Council Grant number 295989. ELA is supported by a UKRI Future Leaders Fellowship (MR/W011581/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
North West Haydock Research Ethics Committee of the UK Health Research Authority gave ethical approval for the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data used in this research are available to researchers that register with UK Biobank and request access to them as part of an approved project.